Application
MDMG-935P may be used for evaluating the expression of fatty acid oxidation (FAO) genes and inflammatory/fibrotic markers, and for assessing liver steatosis.
Biochem/physiol Actions
MDMG-935P is a potent dual, noncompetitive inhibitor of glycolateoxidase (GO) and lactate dehydrogenase A (LDHA), targeting catalytic bindingsites with an IC50 of 9 µM for hLDHA and demonstrating robust in vitro oxalatereduction. It selectively modulates key pathways involved in oxalateoverproduction and upregulates fatty acid oxidation genes, such as CPT1α,showing significant efficacy in reducing liver triglycerides, oxalate levels,and hepatic fibrosis in MASH mouse models at an oral dose of 10 mg/kg. Invitro, Agxt1−/− mouse hepatocytes are employed to model primary hyperoxaluria,and HEK-293 cells are used to assess cytotoxicity. With its favorable metabolicstability, minimal toxicity, anti-fibrotic properties, oral bioavailability, and enhanced efficacy, MDMG-935P is an invaluable tool for investigatinghyperoxaluria and metabolic liver diseases.
| Quality Level | 100 |
| assay | ≥98% (HPLC) |
| form | powder |
| color | white to beige |
| solubility | DMSO: 2 mg/mL, clear (warmed) |
| storage temp. | 2-8°C |
